We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+10.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.02B
AUM Growth
+$67.6M
Cap. Flow
+$92.8M
Cap. Flow %
9.11%
Top 10 Hldgs %
47.33%
Holding
173
New
45
Increased
25
Reduced
30
Closed
56

Top Buys

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$31.8M
2
FOLD
Amicus Therapeutics
FOLD
+$26.7M
3
ZBH icon
Zimmer Biomet
ZBH
+$24.4M
4
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$22.7M
5
INSM icon
Insmed
INSM
+$21.6M

Top Sells

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$17.8M
2
TSRO
TESARO, Inc.
TSRO
+$15.8M
3
EXAS
Exact Sciences
EXAS
+$12.7M
4
ECYT
Endocyte, Inc. Common Stock
ECYT
+$10.4M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 82.29%
2 Miscellaneous 14.83%
3 Consumer Staples 1.81%
4 Financials 1.05%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXAS
126
PUT
DELISTED
Exact Sciences
EXAS
– –
-900,000
Closed -$12.8M
GILD icon
127
Gilead Sciences
GILD
$181B
– –
-50,000
Closed -$3.54M
GMED icon
128
Globus Medical
GMED
$10B
– –
-170,000
Closed -$4.52M
ILMN icon
129
Illumina
ILMN
$33.6B
– –
-2,570
Closed -$372K
LAB icon
130
Standard BioTools
LAB
$271M
– –
-3,070
Closed -$135K
PBYI icon
131
Puma Biotechnology
PBYI
$477M
– –
-735
Closed -$76K
PCRX icon
132
Pacira BioSciences
PCRX
$960M
– –
-2,000
Closed -$139K
RGEN icon
133
PUT
Repligen
RGEN
$9.86B
– –
-45,000
Closed -$579K
RIGL icon
134
Rigel Pharmaceuticals
RIGL
$829M
– –
-5,000
Closed -$194K
FLNA
135
Filana Therapeutics
FLNA
$33.6M
– –
-5,072
Closed -$194K
SNDA icon
136
Sonida Senior Living
SNDA
$1.91B
– –
-13,500
Closed -$5.26M
SRPT icon
137
CALL
Sarepta Therapeutics
SRPT
$2.19B
– –
-350,000
Closed -$8.41M
TNDM icon
138
Tandem Diabetes Care
TNDM
$1.13B
– –
-10,590
Closed -$2.34M
TXMD icon
139
TherapeuticsMD
TXMD
$25M
– –
-140
Closed -$44K
VSTM icon
140
Verastem
VSTM
$665M
– –
-18,333
Closed -$2.39M
ENZ
141
DELISTED
Enzo Biochem, Inc.
ENZ
– –
-380,000
Closed -$1.58M
RAD
142
DELISTED
Rite Aid Corporation
RAD
– –
-746
Closed -$94K
LCI
143
DELISTED
Lannett Company, Inc.
LCI
– –
-1,686
Closed -$241K
ABMD
144
DELISTED
Abiomed Inc
ABMD
– –
-5,000
Closed -$130K
ENDP
145
DELISTED
Endo International plc
ENDP
– –
-1,138
Closed -$78K
VCRA
146
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
– –
-10,000
Closed -$163K
CSLT
147
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
– –
-8,500
Closed -$180K
WMGI
148
DELISTED
Wright Medical Group Inc
WMGI
– –
-10,000
Closed -$311K
STML
149
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-38
Closed -$1K
AGN
150
DELISTED
Allergan plc
AGN
– –
-945
Closed -$195K
3 4 5
6
7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2014 Portfolio in Review

As of Q2 2014, Perceptive Advisors held 173 positions worth $1.02B, up 7.1% from $952M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $92.8M of net new capital in Q2 2014, opening 45 new positions and adding to 25 existing holdings. Its largest new stake was Zimmer Biomet: 249,775 shares worth $25.2M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 81% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was COVIDIEN PLC COM SHS NEW (IRELAND), an estimated $17.8M trimmed.

  • Perceptive Advisors's largest Q2 2014 buy was Zimmer Biomet: 249,775 shares worth $25.2M.
  • Perceptive Advisors added most to QUESTCOR PHARMA INC in Q2 2014, an estimated $31.8M increase.
  • Perceptive Advisors's biggest Q2 2014 reduction was COVIDIEN PLC COM SHS NEW (IRELAND), cutting an estimated $17.8M.
  • Perceptive Advisors fully exited Endocyte, Inc. Common Stock in Q2 2014, selling an estimated $10.4M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.02B portfolio in Q2 2014.
  • Perceptive Advisors opened 45 new positions and closed 56 in Q2 2014.
  • Perceptive Advisors's portfolio value rose 7.1% quarter-over-quarter to $1.02B.

Based on Perceptive Advisors's 13F filing for Q2 2014, filed 14 Aug 2014.